Ozkurt ZN, Sucak GT, Akı SZ, Yağcı M, Erdem O
Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma. [JOURNAL ARTICLE]
Cutan Ocul Toxicol 2009; 28(3):141-143.
Bortezomib is a potent, selective proteasome inhibitor. It is usually well tolerated, and bortezomib-induced skin lesions are less well known. A 59-year-old man with multiple myeloma underwent autologous hematopoetic stem cell transplantation (AHSCT). Administration of bortezomib was started after AHSCT as his disease progressed despite thalidomide maintenance. He developed a rash afer the third cycle of bortezomib. A biopsy showed superficial and deep perivascular dermatitis. The rash resolved within 4 days; complete response of myeloma was obtained after 8 cycles of bortezomib. The benign clinical course did not require interruption of the treatment, which in turn resulted in complete remission of myeloma.
More from this journal |
